Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma.
Boyle EM, Blaney P, Stoeckle JH, Wang Y, Ghamlouch H, Gagler D, Braunstein M, Williams L, Tenenbaum A, Siegel A, Chen X, Varma G, Avigan J, Li A, Jinsi M, Kaminetzsky D, Arbini A, Montes L, Corre J, Rustad EH, Landgren O, Maura F, Walker BA, Bauer M, Bruno B, Tsirigos A, Davies FE, Morgan GJ. Boyle EM, et al. Among authors: corre j. Clin Cancer Res. 2023 Oct 2;29(19):3901-3913. doi: 10.1158/1078-0432.CCR-22-3209. Clin Cancer Res. 2023. PMID: 37449980
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
Aktas Samur A, Fulciniti M, Avet-Loiseau H, Lopez MA, Derebail S, Corre J, Minvielle S, Magrangeas F, Moreau P, Anderson KC, Parmigiani G, Samur MK, Munshi NC. Aktas Samur A, et al. Among authors: corre j. Blood Cancer J. 2022 Dec 20;12(12):171. doi: 10.1038/s41408-022-00759-6. Blood Cancer J. 2022. PMID: 36535935 Free PMC article.
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T, Leleu X, Schavgoulidze A, Chretien ML, Manier S, Adiko D, Orsini-Piocelle F, Lifermann F, Brechignac S, Gastaud L, Bouscary D, Macro M, Cleynen A, Mohty M, Munshi N, Corre J, Avet-Loiseau H. Lannes R, et al. Among authors: corre j. J Clin Oncol. 2023 Mar 20;41(9):1695-1702. doi: 10.1200/JCO.21.01987. Epub 2022 Nov 7. J Clin Oncol. 2023. PMID: 36343306 Free PMC article.
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, Belhadj K, Brechignac S, Frenzel L, Chalopin T, Rey P, Schiano de Collela JM, Dib M, Caillot D, Macro M, Fontan J, Buisson L, Pavageau L, Roussel M, Manier S, Mohty M, Martinet L, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: corre j. Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4. Blood Cancer J. 2023. PMID: 37880285 Free PMC article. No abstract available.
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
Noori S, Wijnands C, Langerhorst P, Bonifay V, Stingl C, Touzeau C, Corre J, Perrot A, Moreau P, Caillon H, Luider TM, Dejoie T, Jacobs JFM, van Duijn MM. Noori S, et al. Among authors: corre j. Blood Cancer J. 2023 Feb 24;13(1):30. doi: 10.1038/s41408-023-00803-z. Blood Cancer J. 2023. PMID: 36828828 Free PMC article. No abstract available.
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.
Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachée-Chardin M, Mansat-De Mas V, Corre J, Récher C, Plat G, Bachelerie F, Donadieu J, Delabesse E. Pasquet M, et al. Among authors: corre j. Blood. 2013 Jan 31;121(5):822-9. doi: 10.1182/blood-2012-08-447367. Epub 2012 Dec 6. Blood. 2013. PMID: 23223431 Free PMC article. Clinical Trial.
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J. Chretien ML, et al. Among authors: corre j. Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11. Haematologica. 2014. PMID: 24727820 Free PMC article.
Blastic island in acute myeloid leukemia.
Corre J, Récher C. Corre J, et al. Blood. 2014 Mar 27;123(13):1986. doi: 10.1182/blood-2013-12-544130. Blood. 2014. PMID: 24800302 Free article. No abstract available.
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D. Devillier R, et al. Among authors: corre j. Oncotarget. 2015 Apr 10;6(10):8388-96. doi: 10.18632/oncotarget.3460. Oncotarget. 2015. PMID: 25860933 Free PMC article.
155 results